Detalhe da pesquisa
1.
Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
Muscle Nerve
; 69(1): 87-92, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990374
2.
The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy.
BMC Neurol
; 23(1): 108, 2023 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932361
3.
Vision Loss as a Presenting Feature of Chronic Inflammatory Demyelinating Polyneuropathy: A Case Series.
J Neuroophthalmol
; 43(1): 48-54, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921552
4.
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
JAMA
; 330(15): 1448-1458, 2023 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37768671
5.
Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.
Heart Fail Rev
; 27(3): 785-793, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33609196
6.
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
Muscle Nerve
; 62(4): 509-515, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32654156
7.
Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.
Muscle Nerve
; 56(5): 901-911, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28063170
8.
Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study.
Orphanet J Rare Dis
; 19(1): 191, 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38720335
9.
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Neurol Ther
; 12(1): 267-287, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36525140
10.
Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells.
Nat Biotechnol
; 41(9): 1229-1238, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36658341
11.
Noncardiac Manifestations of Hereditary Amyloidosis.
Am J Cardiol
; 185 Suppl 1: S17-S22, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36369035
12.
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.
Muscle Nerve
; 53(2): 165-8, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26662952
13.
Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR.
Neurol Ther
; 10(2): 865-886, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34355354
14.
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.
Neurol Ther
; 10(1): 375-389, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33638113
15.
ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.
Orphanet J Rare Dis
; 16(1): 204, 2021 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33957949
16.
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.
J Neurol
; 267(4): 1070-1079, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31853709
17.
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
Expert Rev Clin Pharmacol
; 12(8): 701-711, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31268366
18.
Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment.
Radiother Oncol
; 118(3): 504-9, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26895711
19.
Hepatitis C: a review of its neurologic complications.
Neurologist
; 8(2): 101-6, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12803695
20.
A prospective double-blind, placebo-controlled study of thalidomide sensory symptoms in an elderly population with age-related macular degeneration.
J Clin Neurosci
; 17(5): 571-3, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20223672